SEC Tracker
Get the app

Kalaris Therapeutics KLRS

Kalaris Therapeutics reports Q3 2026 results and business updates

Kalaris Therapeutics (KLRS) filed an 8-K with the SEC on Nov 10, 2026, 7:42 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities: $82.9 million as of September 30, 2026
  2. Phase 1b/2 study data now expected in 2H 2027
  3. Technology transfer to commercial-scale manufacturer completed with test batches meeting specifications
  4. Net loss for Q3 2026 was $11.0 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Kalaris Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.